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Polymorphic metabolic genes that confer enhanced genetic susceptibility to the carcinogenic efect ofcertain environmental carcinogens act according to a type 2 interaction between genetic and environmental risk factors. This type of interaction, for which the gene has no effect on disease outcome byitself but only modifies the risk asociated with exposure, must be treated differently from other types of ge interaction. We present a method to analyz different dose efcts often seen in studies involving these genes. We define a low exposure-gene efect, when a greater deee of gene environment interaction appears at lower dose of exposure (the interaction follows an inverse dose function), and a converse high exposure-gene effict (1) (2) (3) (4) (5) (6) . Despite the importance of environmental exposure in human cancer, the evidence for some form of genetic influence on almost all cancer etiology is very strong (7, 8) . Human Khoury (10, 11) and Ottman (12) . In (13, 14) . If the endpoint is not cancer but, for example, some marker of exposure such as adducts, subjects with polymorphisms should tend to have higher relative levels of adducts at lower doses of exposure; at high exposures, no difference in endpoint would be observed between those with and without the GRF (15) . The LEG effect is very often observed with cases of type 2 GEI such as cancer susceptibility metabolic genes and has been discussed in the context of these genes (16) (17) (18) (19, 20) . However, a study of GSTM1 and asbestosis (21) showed a LEG effect, suggesting that this phenomenon is not simply gene specific, but must be related to the mechanism of action of the gene product leading to the endpoint being measured. It is important to understand that, for both types of doserelated gene-exposure interaction defined here, having the GRF is not protective, and persons with the GRF are at either equal or higher risk than those without the GRF. The difference between the HEG and LEG effects is whether the effect of increasing exposure dose magnifies or diminishes the relative risk associated with the GRF.
We present a method to identify these two patterns of dose effects and illustrate this method with data from a hypothetical case-control study of a metabolic gene polymorphism showing type 2 GEI, as well as with examples from the literature. The method is also able to distinguish between these effects and the presence of a true protective effect of the genetic variant.
Results and Discussion
A common way to describe interactions between the effects of an environmental agent and a genetic risk factor is to use both terms in a multiple regression model and to include a term that multiplies the GRF by the environmental agent. The coefficient of this interactive term then determines whether interaction is present: G(Y) = a+ beE+ bgG+ begEG, (1) where Yis the odds of disease, a is a constant, E is the environmental exposure, G is the GRF, and EG is the interaction term. The coefficients be, b and begare determined by regression analysis using an appropriate computer program. If we assume that in the absence of environmental exposure the presence of the GRF by itself has no effect on disease outcome (which is the definition of type 2 GEI), then b in the regression model of Equation 1 is deined as = 0, which leads to Equation 2: G(Y) = a+ beE+ begEG, (2) which can also be written
This expression corresponds to the assumption that the risk of disease is due to the action only of the environmental exposure and the only effect of the GRF is to modify the coefficient of the exposure term. Now we can say that b* = be+ begG= b(l + aG) (4) where a = beglbe.
In a case-control study, a is the ratio of two log odds ratios (ORs).
For example, let us assume that the effect of GRF such as the isoleucine (Ile) to valine (Val) polymorphism in the CYPlAI gene is to increase the enzymatic activity of the gene product, as has been shown (22) (23) (24) (25) . The result of having this GRF is an increased level of metabolism, presumably leading to an increased concentration of the ultimate carcinogen, given a particular exposure dose.
While this scenario may represent an oversimplification, it can be seen that the effect of the GRF is to quantitatively modify the effect of the exposure term. This would be reflected in a value greater than 0 for the term a. If a is negative, the genetic factor should be protective. If the GRF has no effect on the exposure (e.g., if the exposure is to an agent that is not a substrate for the gene product), then b and a = 0. If the GRF is absent, G = 0. Iwn either case, the risk is a function of exposure only, with no contribution from the gene.
We can rewrite the regression model of Equation 2 if there are data for the effects of multiple (n) levels of exposure (doses): To show the HEG effect, we set the ORs of the three levels of exposure as 2.0, 3.0, and 4.0, the OR for the presence of the genetic polymorphism as 1.0 (as from the definition of GEI type 2), and the OR for the presence of the gene and the three levels of environmental exposure to 3.0, 6.0, and 12.0. To show the LEG response, we kept the same ORs of the three levels of exposure and for the presence of the genetic polymorphism, while the OR for the gene and the three levels of environmental exposure were set to 4.0, 5.0, and 6.0.
The results are presented in Tables 1 and  2 . In Table 1 the value of a rose from 1.1 to 1.7, confirming a HEG effect; in Table 2 (20) illustrate a high exposure-gene effect. Table 3 shows the ORs for each category of smoking exposure and genotype. The first observation is that when the GRF is present but there is no exposure, the OR is equal to the reference (absence of both gene and exposure); this defines a type 2 interaction. As the exposure level increases, the risk of disease increases; the increase is higher when the GRF is present for each category of exposure level. Table 4 shows the coefficients (bp, bQ obtained from the multiple logistic regression model using the SAS statistical package Genmod (SAS Institute, Cary, NC). Also shown in Table  4 are the values for a, the interaction term, which increase directly as a function of dose. Thus, in this case there is a HEG effect. Similar results can be obtained using the data from other sources for this gene and smoking-related lung cancer (19) .
An example of a LEG effect is seen for the CYPIAJ Ile to Val polymorphism in exon 7 of the gene as a GRF for smokinginduced lung cancer. The data from Nakachi et al. (26) , shown in Tables 3 and 4 , show that although the OR for cancer increases for both genotypes as a function of dose, the ratio of the risks decreases at higher doses.
The decrease of a with increasing exposures illustrates this. We have also observed a low exposure-gene effect for the association of the African-American-specific polymorphism in CYPlAl with lung adenocarcinoma in smokers (14) , and other groups have reported similar findings using adducts as an endpoint for NAT2 and for CYPIA2 [Landi et al., personal communication; (15) While at this point the biological mechanisms responsible for the two types of exposure effects are not known, it is possible to speculate that these effects may simply be a reflection of the shape of the dose-response curves for individuals with and without the GRF. If we assume that the effect of a genetic susceptibility factor is to increase the carcinogenic response at any particular dose (e.g., by causing increased enzymatic activity or by altering the metabolic profile of an agent), the dose-response curve will be shifted to the left. An important assumption is that the GRF has no effect on the maximal response. At low dose levels, the presence of the GRF will lead to an increase in the slope of the dose-response curve, and subjects This analytical approach may be used to determine whether a HEG or LEG effect is operative. Type 2 GEI is the correct model for a particular study if the odds ratio for the unexposed group with the GRF is dose to 1. However, when the data are of insufficient statistical power to allow for an accurate determiination of this odds ratio, an alternative is to apply knowledge regarding the mechanism of action of the gene related to the exposure to decide whether a type 2 interaction is logical within a mechanistic context. Comparison of a values between studies and meta-analysis of a for specific gene-exposure combinations may prove valuable in the future. The detection of cancer genetic susceptibility has profound positive public health implications for cancer prevention. Detailed study of the interactions of these genes with environmental carcinogens holds the promise of allowing the definition of subsets of individuals of varying sensitivity and responsiveness. While the entire issue of genetic susceptibility differences among people has important ethical, legal, and political issues, increased knowledge in this area (such as the specific form of exposure-gene effect discussed here) will provide benefits in helping to resolve these issues.
